This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

AZD6765 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese and Caucasian Subjects (JSAD/JMAD)

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: November 3, 2008
Last updated: October 10, 2014
Last verified: October 2014
This is a Phase I randomized double-blind, placebo-controlled, single and multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of AZD6765 in healthy male and female Japanese and Caucasian subjects

Condition Intervention Phase
Healthy Drug: AZD6765 Drug: Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase I, Single-center, Randomized, Double-blind, Placebo-controlled Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6765 in Healthy Male and Female Japanese and Caucasian Subjects

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Safety and tolerability; Adverse events (AEs), vital signs, physical examinations, ECGs and clinical laboratory assessments [ Time Frame: During the study ]

Secondary Outcome Measures:
  • Pharmacokinetic - Pharmacokinetic parameters for AZD6765 in plasma and urine [ Time Frame: During residential period ]
  • Genetics; Collect blood samples for optional exploratory genetic studies focusing on identification of genes that influence the disposition, efficacy, safety and tolerability of AZD6765. [ Time Frame: During the study ]

Enrollment: 40
Study Start Date: November 2008
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: AZD6765
single administration and once daily for 5 days
Placebo Comparator: 2
given (2 subjects in each ethnic/dose group)
Drug: Placebo
single administration and once daily for 5 days


Ages Eligible for Study:   20 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Body mass index (BMI): 18 to 27 kg/m 2
  • Female subjects must be postmenopausal for at least 1 year, surgically sterile, or using a reliable method of contraception at screening.
  • Male subjects must be willing to use accepted contraceptive methods, avoid unprotected sex, and donating sperm until 3 months after drug administration.

Exclusion Criteria:

  • Clinically relevant disease and/or abnormalities (past or present)
  • Clinically relevant abnormalities in physical examinations,vital signs,clinical chemistry, hematology or urinalysis at screening as judged by the investigator
  • Use of any prescription medication within 14 days of Day 1
  • Use of over-the-counter (OTC) medication (with the exception of acetaminophen), vitamin/nutritional supplements and herbal preparations within 14 days of Day 1
  • Smoking in excess of 5 cigarettes per day or the equivalent within 28 days of Day 1
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00785915

United States, California
Research Site
Glendale, California, United States
United States, Maryland
Research Site
Baltimore, Maryland, United States
Sponsors and Collaborators
Principal Investigator: Mark Yen, MD California Clinical Trials
  More Information

Additional Information:
Responsible Party: AstraZeneca Identifier: NCT00785915     History of Changes
Other Study ID Numbers: D6702C00013
Study First Received: November 3, 2008
Last Updated: October 10, 2014

Keywords provided by AstraZeneca:
Japanese and Caucasian Healthy Volunteers
Phase I study
Single and multiple Ascending Dose
Japanese volunteers processed this record on September 21, 2017